Show simple item record

dc.contributor.authorde Jager, VD
dc.contributor.authorTimens, W
dc.contributor.authorBayle, A
dc.contributor.authorBotling, J
dc.contributor.authorBrcic, L
dc.contributor.authorBüttner, R
dc.contributor.authorFernandes, MGO
dc.contributor.authorHavel, L
dc.contributor.authorHochmair, MJ
dc.contributor.authorHofman, P
dc.contributor.authorJanssens, A
dc.contributor.authorJohansson, M
dc.contributor.authorvan Kempen, L
dc.contributor.authorKern, I
dc.contributor.authorLopez-Rios, F
dc.contributor.authorLüchtenborg, M
dc.contributor.authorMachado, JC
dc.contributor.authorMohorcic, K
dc.contributor.authorPaz-Ares, L
dc.contributor.authorPopat, S
dc.contributor.authorRyška, A
dc.contributor.authorTaniere, P
dc.contributor.authorWolf, J
dc.contributor.authorSchuuring, E
dc.contributor.authorvan der Wekken, AJ
dc.coverage.spatialEngland
dc.date.accessioned2024-05-29T13:08:02Z
dc.date.available2024-05-29T13:08:02Z
dc.date.issued2024-03-01
dc.identifierARTN 100838
dc.identifierS2666-7762(24)00004-8
dc.identifier.citationThe Lancet Regional Health - Europe, 2024, 38 pp. 100838 -en_US
dc.identifier.issn2666-7762
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6252
dc.identifier.eissn2666-7762
dc.identifier.eissn2666-7762
dc.identifier.doi10.1016/j.lanepe.2024.100838
dc.identifier.doi10.1016/j.lanepe.2024.100838
dc.description.abstractIn the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the need for predictive molecular tests to identify patients eligible for targeted therapy. This review provides an overview of the development and current application of targeted therapies and predictive biomarker testing in European patients with advanced stage NSCLC. Using data from eleven European countries, we conclude that recommendations for predictive testing are incorporated in national guidelines across Europe, although there are differences in their comprehensiveness. Moreover, the availability of recently EMA-approved targeted therapies varies between European countries. Unfortunately, routine assessment of national/regional molecular testing rates is limited. As a result, it remains uncertain which proportion of patients with metastatic NSCLC in Europe receive adequate predictive biomarker testing. Lastly, Molecular Tumor Boards (MTBs) for discussion of molecular test results are widely implemented, but national guidelines for their composition and functioning are lacking. The establishment of MTB guidelines can provide a framework for interpreting rare or complex mutations, facilitating appropriate treatment decision-making, and ensuring quality control.
dc.formatElectronic-eCollection
dc.format.extent100838 -
dc.languageeng
dc.language.isoengen_US
dc.publisherELSEVIERen_US
dc.relation.ispartofThe Lancet Regional Health - Europe
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.subjectEurope
dc.subjectNon-small cell lung cancer
dc.subjectPredictive biomarker testing
dc.subjectTargeted therapy
dc.titleDevelopments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.en_US
dc.typeJournal Article
dcterms.dateAccepted2024-01-08
dc.date.updated2024-05-29T13:07:34Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1016/j.lanepe.2024.100838en_US
rioxxterms.licenseref.startdate2024-03-01
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/38476742
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.1016/j.lanepe.2024.100838
pubs.volume38
dc.contributor.icrauthorPopat, Sanjay
icr.provenanceDeposited by Mr Arek Surman on 2024-05-29. Deposit type is initial. No. of files: 1. Files: Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their app.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/